atomoxetine
atomoxetine: developed by 1 company · 4 clinical trials tracked · 1 FDA decision.
atomoxetine evidence translation
What we can confirm
1 FDA record · 4 tracked trials
What it means
What to watch
Prepared research question
How could atomoxetine → RDY affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 3 study sponsors
Related indications
No linked indication is available.
Development Pipeline (1)
| Company | Phase |
|---|---|
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
Clinical Trials (4)
Alzheimer's Disease- Systematic Multi-Arm Adaptive Randomised Trial
Primary endpoint: Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score
Atomoxetine Effect on Attention, Executive Function, and Quality of Life in Veterans With Posttraumatic Stress Disorder
Primary endpoint: Behavior Rating Inventory of Executive Function-Adult (BRIEF-A)
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Primary endpoint: Change in Apnea-Hypopnea Index (AHI4) From Baseline: Combined AD109 Arms vs. Placebo
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity Disorder
Primary endpoint: Part A: Change From Baseline in the Cambridge Neuropsychological Test Automated Battery (CANTAB) Reaction Time (RTI) Task at Week 18
FDA Decisions1 records
Frequently asked questions
Who is developing atomoxetine?
atomoxetine is being developed by DR REDDYS LABORATORIES LTD.
How many clinical trials involve atomoxetine?
BioSniper tracks 4 clinical trials involving atomoxetine.
What is atomoxetine's latest FDA decision?
The most recent tracked FDA decision for atomoxetine is Approval for 1 INDICATIONS AND USAGE Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). (1.1) 1.1 Attention-Deficit/Hyperactivity Disorder (ADHD) Atomoxetine capsules are indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The efficacy of atomoxetine capsules was established in seven clinical trials in outpatients with ADHD: four 6 to 9-week trials in pediatric patients (ages 6 , dated February 23, 2018.